Fig. 4

TCDCA suppressed GBM cells through HMGCS1/HMGCR pathway. A The cell viability of U251 cells treated with different concentrations of 200 μM TCDCA and SIN detected by CCK-8 assays (n = 4/group, two-way ANOVA, Sidak's test was performed for the multiple comparison). B Representative images of U251 cells treated with 200 μM TCDCA and 0.5 μM SIN for 24 h in Transwell migration assay. Scale bar, 100 µm. C Quantitative analysis of the numbers of migrated U251 cells (n = 15/group, two-way ANOVA, Sidak's test was performed for the multiple comparison) and cells counted in representative high-power fields per Transwell plate. D Representative images of U251 cells treated with 200 μM TCDCA and 0.5 μM SIN in wound healing assays. Phase-contrast images were acquired at 0 h, 24 h after scratching and representative images of three independent experiments were shown. Scale bars, 200 µm. E Quantitative analysis of the numbers of migrated U251 cells (n = 15/group, two-way ANOVA, Sidak's test was performed for the multiple comparison) and cells counted in representative high-power fields per Transwell plate. F The expression of FAK, p-FAK, Vimentin and N-cadherin in GL261 cells was detected after treated with 200 μM TCDCA for 24 h by western blot. G–J Quantification analysis of the relative FAK (G), p-FAK (H), Vimentin (I), N-cadherin (J) level as shown in (F) (normalized to control, n = 3/group, t-test). Data were mean + SEM. ^*P < 0.05, ^**P < 0.01